Press Releases

Press Releases
Date Title and Summary View
Jun 19, 2017 Presentations highlight innovative research in multiple disease areas including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that data from a broad range ...
Jun 17, 2017 Interim data from the study evaluating the investigational chemotherapy-free R2 combination regimen, presented at ASCO and expanded data presented at ICML Results showed clinical activity across indolent non-Hodgkin lymphomas, marginal zone and follicular histologies, as well as responses...
Jun 14, 2017 Data showed positive trend in multiple disease measures versus placebo Results presented at the Annual European Congress of Rheumatology (EULAR) 2017 BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporat...
Jun 6, 2017 40.3% Overall Response Rate (ORR) with Median Duration of Response of 5.8 Months and 19.3% Complete Response (CR) Rate with Median Duration of Response of 8.8 Months in Patients With a CR Overall Safety Profile was Consistent with Previously Reported Data Simultaneous Online Public...
Jun 5, 2017 - 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 106) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% - - 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete r...
Jun 1, 2017 - Companies expect to report top-line results from the Phase 3 studies in mid-2018 - SUMMIT, N.J. & CAMBRIDGE, Ma.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that they have completed target enrollment in the MEDALIS...
May 22, 2017 Study met the primary endpoint of annualized relapse rate (ARR) and key secondary MRI endpoints of T2 and GdE lesions, compared to interferon (IFN) β-1a (Avonex®); a very low rate of disability progression observed across the three treatment groups in the pooled analysis; disability endpoint not met ...
May 17, 2017 Presentations will include multiple solid tumor and blood cancers while highlighting the value of innovative research SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that data from a broad range of company-sponsored and investigator-initiated studies ...
May 6, 2017 - Preliminary results show that treatment with investigational drug luspatercept achieves meaningful erythroid response rates and transfusion independence in first-line, lower-risk myelodysplastic syndromes patients - - Celgene and Acceleron plan to initiate a Phase 3 trial in first-line,...
May 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.c...
FirstPrevious
2
... NextLast
Add to Briefcase = add release to Briefcase